{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:53:51Z","timestamp":1789206831778,"version":"build-2803163510"},"reference-count":32,"publisher":"Informa UK Limited","issue":"12","funder":[{"name":"Ligue Nationale Fran\u00e7aise contre le Cancer"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.2217\/14622416.8.12.1693","type":"journal-article","created":{"date-parts":[[2007,12,17]],"date-time":"2007-12-17T18:02:59Z","timestamp":1197914579000},"page":"1693-1703","source":"Crossref","is-referenced-by-count":51,"title":["Determination of\n            <i>ERCC2<\/i>\n            Lys751Gln and\n            <i>GSTP1<\/i>\n            Ile105Val Gene Polymorphisms In Colorectal Cancer Patients: Relationships with Treatment Outcome"],"prefix":"10.1080","volume":"8","author":[{"given":"Val\u00e9rie","family":"Le Morvan","sequence":"first","affiliation":[{"name":"Universit\u00e9 Victor Segalen, Institut Bergoni\u00e9, Laboratoire de Pharmacologie des Agents Anticanc\u00e9reux, 229 cours de l\u2018Argonne, 33076 Bordeaux-cedex, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Smith","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint-Andr\u00e9, Centre Hospitalier R\u00e9gional, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armelle","family":"Laurand","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Victor Segalen, Institut Bergoni\u00e9, Laboratoire de Pharmacologie des Agents Anticanc\u00e9reux, 229 cours de l\u2018Argonne, 33076 Bordeaux-cedex, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Brouste","sequence":"additional","affiliation":[{"name":"Unit\u00e9 de recherche clinique, Institut Bergoni\u00e9, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Bellott","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Victor Segalen, Institut Bergoni\u00e9, Laboratoire de Pharmacologie des Agents Anticanc\u00e9reux, 229 cours de l\u2018Argonne, 33076 Bordeaux-cedex, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Soubeyran","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Pathologie, Institut Bergoni\u00e9, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Mathoulin-Pelissier","sequence":"additional","affiliation":[{"name":"Unit\u00e9 de recherche clinique, Institut Bergoni\u00e9, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Robert","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Victor Segalen, Institut Bergoni\u00e9, Laboratoire de Pharmacologie des Agents Anticanc\u00e9reux, 229 cours de l\u2018Argonne, 33076 Bordeaux-cedex, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2007,12,17]]},"reference":[{"key":"e_1_3_2_3_1_1","first-page":"7","article-title":"The frequency of cancer in France in year 2000, and trends since 1950.","volume":"92","author":"Hill C","year":"2005","unstructured":"Hill C , DoyonF: The frequency of cancer in France in year 2000, and trends since 1950.Bull. cancer92 , 7\u201311 (2005).","journal-title":"Bull. cancer"},{"key":"e_1_3_2_3_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi098"},{"key":"e_1_3_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.56.082103.104630"},{"key":"e_1_3_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199753040-00005"},{"key":"e_1_3_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.16.2938"},{"key":"e_1_3_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02034-1"},{"key":"e_1_3_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033025"},{"key":"e_1_3_2_3_8_1","first-page":"42","volume-title":"Curr. Oncol. Rep.","author":"Moses MA","year":"2004","unstructured":"Moses MA , HarperJ, FernandezCA: A role for antiangiogenic therapy in breast cancer.Curr. Oncol. Rep.6 , 42\u201348 (2004)."},{"key":"e_1_3_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.082"},{"key":"e_1_3_2_3_10_1","first-page":"1322","volume":"6","author":"Salonga D","year":"2000","unstructured":"Salonga D , DanenbergKD, JohnsonM et\u00a0al.: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin.Cancer Res.6 , 1322\u20131327 (2000).","journal-title":"Clin.Cancer Res."},{"key":"e_1_3_2_3_11_1","first-page":"8791","volume":"63","author":"Mariadason JM","year":"2003","unstructured":"Mariadason JM , ArangoD, ShiQ et\u00a0al.: Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res.63 , 8791\u20138812 (2003).","journal-title":"Cancer Res."},{"key":"e_1_3_2_3_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602215"},{"key":"e_1_3_2_3_13_1","first-page":"4363","volume":"9","author":"van Kuilenburg AB","year":"2003","unstructured":"van Kuilenburg AB , MeinsmaR, ZonnenbergBA et\u00a0al.: Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity. Clin.Cancer Res.9 , 4363\u20134367 (2003).","journal-title":"Clin.Cancer Res."},{"key":"e_1_3_2_3_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0548"},{"key":"e_1_3_2_3_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.12.936"},{"key":"e_1_3_2_3_16_1","first-page":"8654","volume":"61","author":"Park DJ","year":"2001","unstructured":"Park DJ , StoehlmacherJ, ZhangW et\u00a0al.: A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res.61 , 8654\u20138658 (2001).","journal-title":"Cancer Res."},{"key":"e_1_3_2_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-5002(01)00447-0"},{"key":"e_1_3_2_3_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/18.4.641"},{"key":"e_1_3_2_3_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1363"},{"key":"e_1_3_2_3_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwi018"},{"key":"e_1_3_2_3_21_1","first-page":"1354","volume":"61","author":"Spitz MR","year":"2001","unstructured":"Spitz MR , WuX, WangY et\u00a0al.: Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res.61 , 1354\u20131357 (2001).","journal-title":"Cancer Res."},{"key":"e_1_3_2_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0027-5107(02)00219-1"},{"key":"e_1_3_2_3_23_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1019693504183"},{"key":"e_1_3_2_3_24_1","first-page":"674","volume":"12","author":"Matullo G","year":"2003","unstructured":"Matullo G , PelusoM, PolidoroS et\u00a0al.: Combination of DNA repair gene single nucleotide polymorphisms and increased levels of DNA adducts in a population-based study. Cancer Epidemiol.Biomarkers Prev.12 , 674\u2013677 (2003).","journal-title":"Cancer Epidemiol.Biomarkers Prev."},{"key":"e_1_3_2_3_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/21.4.551"},{"key":"e_1_3_2_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2007.02.010"},{"key":"e_1_3_2_3_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200206000-00010"},{"key":"e_1_3_2_3_28_1","first-page":"1081","volume-title":"Int. J. Cancer","author":"Hartmann C","year":"2004","unstructured":"Hartmann C , XuX, BartelsG et\u00a0al.: PDGFR-\u03b1 in 1p\/19q LOH oligodendrogliomas. Int. J. Cancer112 , 1081\u20131082 (2004)."},{"key":"e_1_3_2_3_29_1","first-page":"3577","volume":"56","author":"Ban N","year":"1996","unstructured":"Ban N , TakahashiY, TakayamaT et\u00a0al: Transfection of glutathione S-transferase (GST)-\u03c0 antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide. Cancer Res.56 , 3577\u20133582 (1996).","journal-title":"Cancer Res."},{"key":"e_1_3_2_3_30_1","first-page":"1859","volume":"2","author":"Nishimura T","year":"1996","unstructured":"Nishimura T , NewkirkK, SessionsRB et\u00a0al.: Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. Clin.Cancer Res.2 , 1859\u20131865 (1996).","journal-title":"Clin.Cancer Res."},{"key":"e_1_3_2_3_31_1","doi-asserted-by":"publisher","DOI":"10.1006\/abbi.1999.1217"},{"key":"e_1_3_2_4_2_1","unstructured":"Developmental therapeutics program http:\/\/dtp.nci.nih.gov"}],"container-title":["Pharmacogenomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/14622416.8.12.1693","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T22:16:15Z","timestamp":1715984175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/14622416.8.12.1693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["10.2217\/14622416.8.12.1693"],"URL":"https:\/\/doi.org\/10.2217\/14622416.8.12.1693","relation":{},"ISSN":["1462-2416","1744-8042"],"issn-type":[{"value":"1462-2416","type":"print"},{"value":"1744-8042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}